ASAistė Skeberdytė

Aistė Skeberdytė

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aistė Skeberdytė has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Ieva Sarapinienė

    Institute of Cardiology, Lithuanian University of Health Sciences, Sukilėlių pr. 15, LT-50162, Kaunas, Lithuania

    2 shared publications
  • Kęstutis Sužiedėlis

    National Cancer Institute, Santariškių g. 1, LT-08660, Vilnius, Lithuania

    2 shared publications
  • Sonata Jarmalaitė

    National Cancer Institute, Santariškių g. 1, LT-08660, Vilnius, Lithuania

    2 shared publications
  • Aušrinė Barakauskienė

    Medicina Practica, P. Baublio g. 4, LT-08406, Vilnius, Lithuania

    1 shared publication
  • Edita Meskinyte-Kausiliene

    Energy and Biotechnology Engineering Institute, Aleksandro Stulginskio University, Studentų g. 11, LT-53361 Akademija, Lithuania

    1 shared publication
  • Ingrida Meskinyte

    Proteomics Center, Institute of Biochemistry, Vilnius University Life Sciences Center, Sauletekio al. 7, LT-10257 Vilnius, Lithuania

    1 shared publication

Latest Publications

  • Salinomycin and dichloroacetate synergistically inhibit Lewis lung carcinoma cell proliferation, tumor growth and metastasis

    by Aistė Skeberdytė, Ieva Sarapinienė, Jan Aleksander Krasko, Aušrinė Barakauskienė, Karolina Žilionytė, Rimvilė Prokarenkaitė, Kęstutis Sužiedėlis, Virginija Bukelskienė, Sonata Jarmalaitė


  • Open Access

    Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines

    by Aistė Skeberdytė, Ieva Sarapinienė, Jan Aleksander-Krasko, Vaidotas Stankevičius, Kęstutis Sužiedėlis, Sonata Jarmalaitė

    In the present study, we examined a hypothesis that dichloroacetate, a metabolic inhibitor, might efficiently potentiate the cytotoxic effect of salinomycin, an antibiotic ionophore, on two human colorectal cancer derived cell lines DLD-1 and HCT116. First, we performed a series of dose response experiments in the 2D cell culture by applying mono- and combination therapy and by using the Chou-Talalay method found that salinomycin in combination with dichloroacetate acted synergistically in both cell lines. Secondly, in order to recapitulate the in vivo tumor architecture, we tested various doses of these compounds, alone and in combination, in the 3D multicellular spheroid culture. The effect of combination of dichloracetate and salinomycin on multicellular spheroid size was stronger than the sum of both monotherapies, particularly in HCT116 cells. Further, we demonstrate that the synergistic effect of compounds may be related to the inhibitory effect of dichloroacetate on multidrug resistance proteins, and in contrast, it is not related to dichloroacetate-induced reduction of intracellular pH. Our findings indicate that the combination therapy of salinomycin and dichloroacetate could be an effective option for colorectal cancer treatment and provide the first mechanistic explanation of the synergistic action of these compounds.


  • Top Cited Papers
    Open Access

    KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

    by Jonas Cicenas, Kotryna Kvederaviciute, Ingrida Meskinyte, Edita Meskinyte-Kausiliene, Aiste Skeberdyte, Jonas Cicenas

    Pancreatic cancer is a disease that has a very high fatality rate and one of the highest mortality ratios among all major cancers, remaining the fourth leading cause of cancer-related deaths in developed countries. The major treatment of pancreatic cancer is surgery; however, only 15–20% of patients are candidates for it at the diagnosis of disease. On the other hand, survival in patients, who undergo surgery, is less than 30%. In most cancers, genome stability is disturbed and pancreatic cancer is not the exception. Approximately 97% of pancreatic cancers have gene derangements, defined by point mutations, amplifications, deletions, translocations, and inversions. This review describes the most frequent genetic alterations found in pancreatic cancer.